𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Norfloxacin prevents spontaneous bacterial peritonitis (SBP) in cirrhosis. Final results of a multicenter double-blind placebo controled study

✍ Scribed by Ginès, P; Rimola, A; Planas, R; Vargas, V; Forné, M; Miranda, ML; Rodrigo, L; del Val, A; Marco, F; Almela, H

Book ID
122727340
Publisher
Elsevier Science
Year
1990
Tongue
English
Weight
107 KB
Volume
11
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Norfloxacin prevents spontaneous bacteri
Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial
✍ Dr. Pere Ginés; Antoni Rimola; Ramón Planas; Victor Vargas; Francesc Marco; Manu 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 958 KB

Eighty cirrhotic patients who had recovered from an episode of spontaneous bacterial peritonitis were included in a multicenter, double-blind trial aimed at comparing long-term norfloxacin administration (400 mglday; 40 patients) vs. placebo (40 patients) in the prevention of spontaneous bacterial p

Two different dosages of cefotaxime in t
Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study
✍ Antoni Rimola; Joan M. Salmerón; Gerardo Clemente; Luis Rodrigo; Antoni Obrador; 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 741 KB

Cefotaxime (CTX) is considered one of the first-choice antibiotics in the therapy of spontaneous bacterial peritonitis (SBP) in cirrhosis. Because CTX is largely metabolized in the liver, this drug may also be effective in SBP by administering lower doses than those habitually used. To investigate t